Vasopressin and V2 Receptor in Meniere's Disease

NCT00599560 | Completed

• 2 other identifiers: tk19661218Osaka Univ. School of Medicine
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 1

Brief Summary

Summary: Some of sicknesses are well known to be provoked by inadequate adaptation to physical and/or psychogenic stress in their daily life. Meniere's disease is also a common inner ear disease accompanied with vertigo, hearing loss and tinnitus especially in civilized people under stressed life style. Its oto-pathology was firstly revealed in 1938 to be inner ear endolymphatic hydrops through the temporal bone study. To elucidate the neuroscientific relationship between "stress" and "inner ear", we examined plasma vasopressin (the anti-diuretic "stress" hormone) and its receptor, V2R in the endolymphatic sac (the "inner ear" endo-organ for endolymph absorption) in Meniere's patients.

Conditions

Meniere Disease

Keywords

Meniere's disease; stress; vasopressin; endolymphatic sac; V2 receptor; cyclic AMP; Plasma vasopressin level and V2R mRNA expression level in the endolymphatic sac both were significantly higher in patients with Meniere's disease.; In Meniere's disease, there were significant negative co-relationships between vasopressin and V2R.; The cyclic AMP activity was basically up-regulated in the endolymphatic sac in Meniere's disease..; The cyclic AMP sensitivity for vasopressin was significantly elevated in the endolymphatic sac in Meniere's disease.

Outcome Measures

Primary Outcomes (1)

• plasma vasopressin level and V2 receptor mRNA in the endolymphatic sac in Meniere's disease vs controls

  prospective

Secondary Outcomes (1)

• cyclic AMP activity in the endolymphatic sac in Meniere's disease vs controls

  prospective

Study Arms (2)

1. Meniere's disease

EXPERIMENTAL

Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.

Genetic: vasopressin, V2 receptor and cyclic AMP

2. Acoustic neurinoma

NO INTERVENTION

Diagnosed by CT and/or MRI

Interventions

vasopressin, V2 receptor and cyclic AMP GENETIC

plasma vasopressin, V2 receptor, cyclic AMP

Also known as: plasma vasopressin, V2 receptor, cyclic AMP

1. Meniere's disease

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows:
• Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks.
• Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.

You may not qualify if:

• Any other neuro-otologic diseases.

Sponsors & Collaborators

• Osaka University: lead
• Osaka City University: collaborator

Study Sites (1)

Department of Otolaryngology, Osaka University, School of Medicine

Suita, Osaka, 565-0871, Japan

Location

Related Publications (1)

• Kumagami H, Beitz E, Wild K, Zenner HP, Ruppersberg JP, Schultz JE. Expression pattern of adenylyl cyclase isoforms in the inner ear of the rat by RT-PCR and immunochemical localization of calcineurin in the organ of Corti. Hear Res. 1999 Jun;132(1-2):69-75. doi: 10.1016/s0378-5955(99)00035-0.

  PMID: 10392549 RESULT

Related Links

• Meniere's disease group at Department of ORL, Osaka University, School of Medicine

MeSH Terms

Conditions

Meniere Disease; Diabetes Insipidus; Diabetes Insipidus, Nephrogenic

Interventions

Vasopressins; Receptors, Vasopressin; Cyclic AMP

Condition Hierarchy (Ancestors)

Endolymphatic Hydrops; Labyrinth Diseases; Ear Diseases; Otorhinolaryngologic Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Receptors, Neuropeptide; Receptors, Neurotransmitter; Receptors, Peptide; Receptors, Pituitary Hormone; Adenine Nucleotides; Purine Nucleotides; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nucleotides, Cyclic; Nucleotides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleotides

Study Officials

• Tadashi Kitahara, M.D.,Ph.D.

  Department of ORL, Osaka University, School of Medicine

  PRINCIPAL INVESTIGATOR

• Hiroshi Kiyama, Ph.D.

  Department of Neuroanatomy, Osaka City University, School of Medicine

  STUDY DIRECTOR

• Takeshi Kubo, M.D.,Ph.D.

  Department of ORL, Osaka University, School of Medicine

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: January 10, 2008
• First Posted: January 23, 2008
• Study Start: April 1, 1998
• Primary Completion: September 1, 2005
• Study Completion: September 1, 2005
• Last Updated: March 29, 2016

Record last verified: 2008-01

Locations

JP (1)